Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Minority Interest (2017 - 2025)

Serina Therapeutics' Minority Interest history spans 9 years, with the latest figure at -$166000.0 for Q3 2025.

  • For Q3 2025, Minority Interest fell 207.41% year-over-year to -$166000.0; the TTM value through Sep 2025 reached -$166000.0, down 207.41%, while the annual FY2024 figure was -$133000.0, 100.37% down from the prior year.
  • Minority Interest for Q3 2025 was -$166000.0 at Serina Therapeutics, down from -$156000.0 in the prior quarter.
  • Across five years, Minority Interest topped out at $36.4 million in Q4 2023 and bottomed at -$166000.0 in Q3 2025.
  • The 5-year median for Minority Interest is -$49500.0 (2022), against an average of $1.9 million.
  • The largest annual shift saw Minority Interest soared 35443.69% in 2023 before it tumbled 420.0% in 2025.
  • A 5-year view of Minority Interest shows it stood at -$43000.0 in 2021, then crashed by 139.53% to -$103000.0 in 2022, then skyrocketed by 35443.69% to $36.4 million in 2023, then plummeted by 100.37% to -$133000.0 in 2024, then dropped by 24.81% to -$166000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Minority Interest are -$166000.0 (Q3 2025), -$156000.0 (Q2 2025), and -$142000.0 (Q1 2025).